Intravitreal dexamethasone implant treatment in patients with diabetic macular edema resistant to anti-vegf treatment

2021 ◽  
Vol 30 (2) ◽  
pp. 152
Author(s):  
Meltem Güzin Altınel ◽  
Haşim Uslu ◽  
Ayşe Yağmur Kanra
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Dexamethasone Implant ◽  
Anti Vegf ◽  
Intravitreal Dexamethasone Implant ◽  
Intravitreal Dexamethasone ◽  
Implant Treatment

scholarly journals Effectiveness of Intravitreal Dexamethasone Implant Treatment for Diabetic Macular Edema in Vitrectomized Eyes

2019 ◽  
Vol 49 (6) ◽  
pp. 323-327
Author(s):  
Hüseyin Baran Özdemir ◽  
Murat Hasanreisoğlu ◽  
Murat Yüksel ◽  
Mestan Ertop ◽  
Gökhan Gürelik ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Dexamethasone Implant ◽  
Intravitreal Dexamethasone Implant ◽  
Intravitreal Dexamethasone ◽  
Implant Treatment

scholarly journals Combined Intravitreal Dexamethasone Implant And Micropulse Yellow Laser For Treatment Of Anti-VEGF Resistant Diabetic Macular Edema

2017 ◽  
Vol 11 (1) ◽  
pp. 164-172 ◽  
Author(s):  
Ahmed Hosni Abd Elhamid
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Secondary Outcome ◽  
Dexamethasone Implant ◽  
Micropulse Laser ◽  
Anti Vegf ◽  
Intravitreal Dexamethasone Implant ◽  
Yellow Laser ◽  
The Mean ◽  
Intravitreal Dexamethasone

Purpose:To report the efficacy and safety of combined intravitreal dexamethasone implant and micropulse laser for anti-VEGF resistant diabetic macular edema.Patients and Methods:Prospective, non-controlled study that was conducted for twenty eyes with center-involved diabetic macular edema not responding to anti-VEGF therapy. Ozurdex intravitreal implant was injected to all eyes with subsequent micropulse yellow laser one month after the injection. All eyes were followed up after one, three, four, six, nine and twelve months. The primary outcome measure is the change in best corrected visual acuity (BCVA) after one year and secondary outcome measures are central macular thickness (CMT) change and safety of both dexamethasone implant and micropulse laser. Reinjection was done for those eyes with recurrent edema.Results:The mean age was 58.8 ±7.94 years. The mean BCVA was 0.6± 0.14, 0.57 ±0.12, 0.51±0.15, 0.59±0.12, 0.6± 0.12 and 0.59±0.14 after one, three, four, six, nine and twelve months in comparison to 0.45± 0.14 as initial BCVA [SS,P<0.05]. The CMT was 302.5±30.01, 330.6±20.24, 357.6±32.15, 285.4±19.95, 292.9±25.07 and 285.2±14.99µm after one ,three, four ,six , nine and twelve months in comparison to initial CMT of 420.7 ±38.74µm [HS, P<0.01]. Cataract occurred in 6 eyes from 14 phakic eyes (42.8%). Transient ocular hypertension occurred in 6 eyes (30%). Reinjection was done for eight eyes (40%).Conclusion:Intravitreal dexamethasone implant and micropulse laser are both effective and safe treatment options for anti-VEGF resistant diabetic macular edema.

Sign in / Sign up

Export Citation Format

Share Document